131 related articles for article (PubMed ID: 35609158)
1. Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse.
Prasad RM; Srivastava S; Wang E; Liu JZ; Gami R; Abdelgadir A; Sharma A; Rayamajhi S; Tikaria R
Perm J; 2021 Oct; 26(1):123-131. PubMed ID: 35609158
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
Rodriguez-Pla A; Vikram HR; Khalid V; Wesselius LJ
Rheumatol Int; 2021 Aug; 41(8):1509-1514. PubMed ID: 34091704
[TBL] [Abstract][Full Text] [Related]
3. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
4. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.
Ormazabal Vélez I; Induráin Bermejo J; Espinoza Pérez J; Imaz Aguayo L; Delgado Ruiz M; García-Erce JA
Transfus Apher Sci; 2021 Jun; 60(3):103104. PubMed ID: 33637467
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
6. Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use.
Adedoyin O; Brijmohan S; Lavine R; Lisung FG
BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34844968
[TBL] [Abstract][Full Text] [Related]
7. Impact of rituximab on COVID-19 outcomes.
Levavi H; Lancman G; Gabrilove J
Ann Hematol; 2021 Nov; 100(11):2805-2812. PubMed ID: 34549309
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis.
Curtò D; Tomatis F; Gastoldi S; Galbusera M; Noris M; Raimondi F; Lorini FL; Falanga A; Marchetti M; Remuzzi G; Ruggenenti P
Front Immunol; 2021; 12():711915. PubMed ID: 34276706
[TBL] [Abstract][Full Text] [Related]
9. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
Etemadifar M; Sigari AA; Sedaghat N; Salari M; Nouri H
Hum Vaccin Immunother; 2021 Oct; 17(10):3481-3483. PubMed ID: 34015240
[TBL] [Abstract][Full Text] [Related]
10. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
Trials; 2021 May; 22(1):342. PubMed ID: 34001174
[TBL] [Abstract][Full Text] [Related]
11. Pemphigus vulgaris relapse during the coronavirus disease pandemic.
Saleh MA; Saleh NA
Dermatol Ther; 2022 Apr; 35(4):e15354. PubMed ID: 35108427
[TBL] [Abstract][Full Text] [Related]
12. Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series.
Sakano T; Bittner EA; Chang MG
Postgrad Med; 2022 Mar; 134(2):239-243. PubMed ID: 35129061
[TBL] [Abstract][Full Text] [Related]
13. Treatment of immunocompromised COVID-19 patients with convalescent plasma.
Fung M; Nambiar A; Pandey S; Aldrich JM; Teraoka J; Freise C; Roberts J; Chandran S; Hays SR; Bainbridge E; DeVoe C; Roque Gardner A; Yokoe D; Henrich TJ; Babik JM; Chin-Hong P
Transpl Infect Dis; 2021 Apr; 23(2):e13477. PubMed ID: 32989856
[TBL] [Abstract][Full Text] [Related]
14. Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway.
D'Abramo A; Vita S; Maffongelli G; Beccacece A; Agrati C; Cimini E; Colavita F; Giancola ML; Cavasio A; Nicastri E;
Front Immunol; 2022; 13():911339. PubMed ID: 35711444
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
[TBL] [Abstract][Full Text] [Related]
16. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
Delgado-Fernández M; García-Gemar GM; Fuentes-López A; Muñoz-Pérez MI; Oyonarte-Gómez S; Ruíz-García I; Martín-Carmona J; Sanz-Cánovas J; Castaño-Carracedo MÁ; Reguera-Iglesias JM; Ruíz-Mesa JD
Enferm Infecc Microbiol Clin (Engl Ed); 2022 Nov; 40(9):507-516. PubMed ID: 36336380
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.
Gupta A; Kute VB; Patel HV; Engineer DP; Banerjee S; Modi PR; Rizvi SJ; Mishra VV; Patel AH; Navadiya V
Exp Clin Transplant; 2021 Apr; 19(4):304-309. PubMed ID: 33605203
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of rituximab for the management of adult-onset steroid-dependent nephrotic syndrome: a retrospective study.
Katsuno T; Masuda T; Saito S; Kato N; Ishimoto T; Kato S; Kosugi T; Tsuboi N; Kitamura H; Tsuzuki T; Ito Y; Maruyama S
Clin Exp Nephrol; 2019 Feb; 23(2):207-214. PubMed ID: 30121802
[TBL] [Abstract][Full Text] [Related]
19. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review.
Valk SJ; Piechotta V; Chai KL; Doree C; Monsef I; Wood EM; Lamikanra A; Kimber C; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2020 May; 5(5):CD013600. PubMed ID: 32406927
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab.
Boyer-Suavet S; Andreani M; Lateb M; Savenkoff B; Brglez V; Benzaken S; Bernard G; Nachman PH; Esnault V; Seitz-Polski B
Front Immunol; 2019; 10():3069. PubMed ID: 31998325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
